AI Article Synopsis
- Antineoplastic drugs are classified into irritants, vesicants, and non-vesicants based on their local damage potential, with vesicants historically linked to higher rates of extravasation (EV) incidents.
- A case report describes a 55-year-old woman with esophageal squamous cell carcinoma who experienced grade III EV after receiving the irritant drug 5-fluorouracil during her chemotherapy regimen.
- The drug was stopped immediately, the patient recovered by the next cycle, and this highlights the necessity for preventive measures and awareness, as there is no effective antidote for managing EV.
Article Abstract
Antineoplastic drugs based on their ability to cause local damage are classified as irritants, vesicants, and non-vesicants. Previous literature has reported higher rate of vesicants induced extravasation (EV) compared to irritants. We report the first case of irritant, 5-fluorouracil causing grade III EV in 55-year-old woman. The patient was diagnosed with esophageal squamous cell carcinoma. Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) chemotherapy regimen was planned and administered through peripheral venous access. Patient experienced grade 3 extravasation in her 3 cycle following 5-fluorouracil (5-FU) administration. The suspected drug was withdrawn immediately and discontinued from the 4 cycle of the regimen. The patient completely recovered from the symptoms of pain and erythema in the next cycle and care was taken not to infuse drug in the same site again. Since there is no appropriate antidote available to manage this condition, measures need to be taken to identify the predisposing factors for EV and prevent them.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijc.IJC_281_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!